Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RHO Clear all
Completed Phase 3 Interventional

The Effects of Atorvastatin in Patients With Atherosclerosis

NCT00115817
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Sep 6, 2026, 10:04 AM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 6, 2026, 10:04 AM EDT
Active, not recruiting Not applicable Interventional

Prospective Natural History Study of Retinitis Pigmentosa

NCT04285398
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Ophthalmic examinations, Mobility Test
Other
Lead sponsor
SparingVision
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Available No phase listed Expanded access

Expanded Access Program for RP in Adults

NCT06574997
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
OCU400
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years to 99 Years
U.S. locations
5
States / cities
Phoenix, Arizona • Deerfield Beach, Florida • Erie, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 10:04 AM EDT
Withdrawn Phase 2 Interventional

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

NCT04956276
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 6, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096
View directory record Official record
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Metabolism of Danicopan in Healthy Adults

NCT04609696
View directory record Official record
Conditions
Healthy
Interventions
Danicopan: Powder-In-Capsule 1, Danicopan: Powder-In-Capsule 2, Danicopan: Tablet
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 6, 2026, 10:04 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085
View directory record Official record
Conditions
Impaired Hepatic Function, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 6, 2026, 10:04 AM EDT
Active, not recruiting Phase 2 Interventional

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

NCT05218668
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Fasudil (WP-0512)
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 6, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Fasudil Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants

NCT01994954
View directory record Official record
Conditions
Premature Infants
Interventions
RHO
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 37 Weeks
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Farmington, Connecticut • Lexington, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2023 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Tai Chi for Bone Health

NCT00625391
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Green Tea Polyphenols (GTP), Placebo+Tai Chi (TC), GTP+TC
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Female only
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Rho Kinase in Patients With Atherosclerosis

NCT00115830
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294
View directory record Official record
Conditions
Healthy, Renal Dysfunction
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 6, 2026, 10:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

NCT02867618
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-hodgkin
Interventions
Carfilzomib, TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Hepatic Impairment

NCT03555539
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 6, 2026, 10:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Promising ROd-cone DYstrophy Gene therapY

NCT05748873
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
SPVN06
Drug
Lead sponsor
SparingVision
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 6, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 6, 2026, 10:04 AM EDT
Recruiting Phase 1 Interventional

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

NCT06075810
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Interventions
MBQ-167
Drug
Lead sponsor
MBQ Pharma
Industry
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Beverly Hills, California • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 10:04 AM EDT